Operation

Stem cells are progenitor cells that constitute a kind of "primordial soup" of life. Stem cells differentiate into different cell types and therefore into different organs over the course of their development.


TICEBA - Degree of differentiation

A specific type of cell that is to be found in most tissues and which is not yet determined with regard to its future form is called "pluripotent adult stem cell". These stem cells may be "programmed" by the surrounding tissue to take on any form - from heart tissue to spinal marrow neuronal cells to whole organs. These adult stem cells are found in great numbers in the skin, the biggest organ of the human organism.

Stem cells exist to replace old cells that have died off in order to guarantee the renewed function of cell groups or organs. When using autologous stem cells, no rejection occurs, as happens frequently with tissue that is strange to the body! Nothing is as compliant to the body as its own cells.

News
Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter